Jessica L. Maples-Keller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessica L. Maples-Keller has a total of 402 co-authors. Here are the top co-authors by number of shared publications:
Barbara O. Rothbaum
Emory University School of Medicine
10 shared publications- Barbara Olasov Rothbaum
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA
9 shared publications - Sheila A. M. Rauch
Emory University School of Medicine
8 shared publications Tanja Jovanovic
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, USA
6 shared publications- Vasiliki Michopoulos
Emory University
6 shared publications - Andrew M. Sherrill
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
4 shared publications
Latest Publications
- 26 May 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (2) , 103-112
Qualitative Analysis of Views of Psychedelic-Assisted Therapy in Low-Income, Urban, Black Americans
Introduction: Black Americans are significantly underrepresented in psychedelic trials despite significant mental health disparities. Growing research suggests that psychedelic-assisted therapy (PAT) is an effective treatment for post-traumatic stress disorder and depression. It is important to understand perceptions of PAT among populations with unmet mental health needs. Methods: We conducted four focus groups to understand perceptions of psychedelic therapy within a low-income, Black, urban population. Methods: Three main themes were identified using an inductive thematic analysis approach: (1) informed hesitation mixed with increasing openness; (2) trust, autonomy, and choice; and (3) practical solutions to increase accessibility. Conclusions: Participants described many concerns related to legacies of racism in healthcare, research, drug prescription, and criminalization. Healthcare systems must invest in trust building with Black Americans to adequately meet healthcare needs. Participants emphasized ways of building trust through supporting autonomy and choice, investing in community building and agency, and suggestions to address barriers (e.g., providing childcare, providing transportation). These findings support calls to center the needs of Black American people given the lack of culturally salient therapeutic paradigms specifically for Black Americans utilized within PAT, improve access and address barriers to healthcare for Black Americans, and increase the quality of care available.
- 26 May 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (2) , 103-112
Qualitative Analysis of Views of Psychedelic-Assisted Therapy in Low-Income, Urban, Black Americans
Introduction: Black Americans are significantly underrepresented in psychedelic trials despite significant mental health disparities. Growing research suggests that psychedelic-assisted therapy (PAT) is an effective treatment for post-traumatic stress disorder and depression. It is important to understand perceptions of PAT among populations with unmet mental health needs. Methods: We conducted four focus groups to understand perceptions of psychedelic therapy within a low-income, Black, urban population. Methods: Three main themes were identified using an inductive thematic analysis approach: (1) informed hesitation mixed with increasing openness; (2) trust, autonomy, and choice; and (3) practical solutions to increase accessibility. Conclusions: Participants described many concerns related to legacies of racism in healthcare, research, drug prescription, and criminalization. Healthcare systems must invest in trust building with Black Americans to adequately meet healthcare needs. Participants emphasized ways of building trust through supporting autonomy and choice, investing in community building and agency, and suggestions to address barriers (e.g., providing childcare, providing transportation). These findings support calls to center the needs of Black American people given the lack of culturally salient therapeutic paradigms specifically for Black Americans utilized within PAT, improve access and address barriers to healthcare for Black Americans, and increase the quality of care available.
- Open Access
- 29 April 2025
- Published by Genomic Press in Psychedelics
- Vol. 1 (2) , 31-39
What motivates spiritual health practitioners in psychedelic-assisted therapy? A qualitative study and implications for facilitator training practices
Spiritual health practitioners (SHPs), also known as healthcare chaplains, are increasingly involved in facilitating psychedelic-assisted therapies in clinical trials and community settings. Although the motivations of therapeutic practitioners are known to impact clinical decision-making and treatment outcomes, little research has investigated what drives SHPs to pursue this work. This qualitative study examined n = 15 SHP's (60% female; MAge = 46.57) who were involved in legal administration of psychedelic-assisted therapy. An inductive-deductive qualitative analysis approach yielded two major themes: (1) Initial Motivation for Practicing PAT, and (2) Ongoing Sources of Meaning and Fulfillment. The SHPs in this study often cited personal experiences as key motivations for entering this field, frequently linked to a significant personal encounter with psychedelic use. The most common Ongoing Sources of Meaning and Fulfillment included witnessing healing in others and experiencing positive personal impacts from facilitating psychedelic-assisted care. This article addresses the substantial role that personal psychedelic experiences appear to play in SHPs’ motivations to pursue this area of practice. Such experiences provide valuable first-hand knowledge of the unique phenomenology of psychedelic treatment, although they can also potentially introduce biases and reduce objectivity. Training and certification guidelines set by the Association for Clinical Pastoral Education (ACPE) may help address these risks for SHPs through heavy emphasis placed on self-literacy and reflective learning components. Guided by these findings, we introduce a novel reflective learning exercise, as well as several existing ACPE learning components that may support psychedelic facilitators and facilitators-in-training from any professional background.
- 29 April 2025
- Published by Genomic Press in Psychedelics
- Vol. 1 (2) , 31-39
Open AccessWhat motivates spiritual health practitioners in psychedelic-assisted therapy? A qualitative study and implications for facilitator training practices
Spiritual health practitioners (SHPs), also known as healthcare chaplains, are increasingly involved in facilitating psychedelic-assisted therapies in clinical trials and community settings. Although the motivations of therapeutic practitioners are known to impact clinical decision-making and treatment outcomes, little research has investigated what drives SHPs to pursue this work. This qualitative study examined n = 15 SHP's (60% female; MAge = 46.57) who were involved in legal administration of psychedelic-assisted therapy. An inductive-deductive qualitative analysis approach yielded two major themes: (1) Initial Motivation for Practicing PAT, and (2) Ongoing Sources of Meaning and Fulfillment. The SHPs in this study often cited personal experiences as key motivations for entering this field, frequently linked to a significant personal encounter with psychedelic use. The most common Ongoing Sources of Meaning and Fulfillment included witnessing healing in others and experiencing positive personal impacts from facilitating psychedelic-assisted care. This article addresses the substantial role that personal psychedelic experiences appear to play in SHPs’ motivations to pursue this area of practice. Such experiences provide valuable first-hand knowledge of the unique phenomenology of psychedelic treatment, although they can also potentially introduce biases and reduce objectivity. Training and certification guidelines set by the Association for Clinical Pastoral Education (ACPE) may help address these risks for SHPs through heavy emphasis placed on self-literacy and reflective learning components. Guided by these findings, we introduce a novel reflective learning exercise, as well as several existing ACPE learning components that may support psychedelic facilitators and facilitators-in-training from any professional background.
- Open Access
- 19 April 2025
- Published by Elsevier in Journal of Mood & Anxiety Disorders
- Vol. 11, 100123
Personality traits as predictors of PTSD and depression symptoms following exposure-based treatment in an intensive outpatient program
- 19 April 2025
- Published by Elsevier in Journal of Mood & Anxiety Disorders
- Vol. 11, 100123
Open AccessPersonality traits as predictors of PTSD and depression symptoms following exposure-based treatment in an intensive outpatient program
- Open Access
- 17 December 2024
- Published by Genomic Press in Psychedelics
- Vol. 1 (1) , 32-38
Reading the crowd: attitudes toward psychedelics and psychedelic therapies among attendees at a conference
Social attitudes, policy, and perceptions of psychedelics are currently undergoing considerable change. Growing public salience of psychedelics has been accompanied by the emergence of conferences focused on psychedelic education and dialogue. Attendees at such events compose an important group of stakeholders in psychedelic science and practice; their views of psychedelics can be valuable for understanding the current status of this emerging field. For this study, a survey was administered to attendees (N = 178) at an academic conference focused on two topics: psychedelics and spiritual care. The survey queried attitudes toward psychedelics in emerging research domains: 1) the potential benefits of microdosing and 2) potential for harm with psychedelics use. A subset of attendees who were facilitators of psychedelic care (n = 32) were also asked about their facilitation practices and their beliefs concerning aspects of psychedelic facilitation. Participants generally agreed that microdosing may have benefits (M = 3.90, where 4 = Probably, SD = 0.95) and modest concern (40.2% (n = 72) agreed or strongly agreed and 30.7% (n = 55) respondents “not sure”) that psychedelics could be harmful when used therapeutically. Descriptive analyses of a subset of psychedelic care facilitators also characterized harms observed during psychedelic care. Psychedelic care facilitators reported that they used psychedelics to treat a wide range of diagnoses, employing diverse psychotherapy modalities, and endorsed a need for cultural adaptations among psychedelic treatments.
- 17 December 2024
- Published by Genomic Press in Psychedelics
- Vol. 1 (1) , 32-38
Open AccessReading the crowd: attitudes toward psychedelics and psychedelic therapies among attendees at a conference
Social attitudes, policy, and perceptions of psychedelics are currently undergoing considerable change. Growing public salience of psychedelics has been accompanied by the emergence of conferences focused on psychedelic education and dialogue. Attendees at such events compose an important group of stakeholders in psychedelic science and practice; their views of psychedelics can be valuable for understanding the current status of this emerging field. For this study, a survey was administered to attendees (N = 178) at an academic conference focused on two topics: psychedelics and spiritual care. The survey queried attitudes toward psychedelics in emerging research domains: 1) the potential benefits of microdosing and 2) potential for harm with psychedelics use. A subset of attendees who were facilitators of psychedelic care (n = 32) were also asked about their facilitation practices and their beliefs concerning aspects of psychedelic facilitation. Participants generally agreed that microdosing may have benefits (M = 3.90, where 4 = Probably, SD = 0.95) and modest concern (40.2% (n = 72) agreed or strongly agreed and 30.7% (n = 55) respondents “not sure”) that psychedelics could be harmful when used therapeutically. Descriptive analyses of a subset of psychedelic care facilitators also characterized harms observed during psychedelic care. Psychedelic care facilitators reported that they used psychedelics to treat a wide range of diagnoses, employing diverse psychotherapy modalities, and endorsed a need for cultural adaptations among psychedelic treatments.
- Open Access
- 24 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 43, 101400
The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD
- 24 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 43, 101400
Open AccessThe METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD
- 31 July 2024
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 38 (8) , 690-700
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed. Methods: A multidisciplinary working group of experts involved in PAT pooled formally and informally documented AEs observed through research experience and published literature. This information was integrated with (a) current standards and practices for AE reporting in pharmacotherapy and psychotherapy trials and (b) published findings documenting post-acute dosing impacts of psychedelics on subjective states, meaning, and psychosocial health variables, to produce a set of AE constructs important to evaluate in PAT as well as recommended methods and time frames for their assessment and monitoring. Correspondence between identified potential AEs and current standards for AE assessment was examined, including the extent of coverage of identified AE constructs by 25 existing measures used in relevant research. Results: Fifty-four potential AE terms warranting systematized assessment in PAT were identified, defined, and categorized. Existing measures demonstrated substantial gaps in their coverage of identified AE constructs. Recommendations were developed for how to assess PAT AEs (including patient, clinician, and informant reports), and when to assess over preparation, dosing session, integration, and follow-up. Application of this framework is demonstrated in a preliminary assessment protocol (available in the supplement). Conclusions: This assessment framework addresses the need to capture post-acute dosing AEs in PAT, accounting for its pharmacotherapy and psychotherapy components, as well as documented impacts of psychedelics on worldviews and spirituality.
- 31 July 2024
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 38 (8) , 690-700
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment of adverse events (AEs) in PAT research has lagged. Current AE reporting standards in PAT trials are poorly calibrated to features of PAT that distinguish it from other treatments, leaving many potential AEs unassessed. Methods: A multidisciplinary working group of experts involved in PAT pooled formally and informally documented AEs observed through research experience and published literature. This information was integrated with (a) current standards and practices for AE reporting in pharmacotherapy and psychotherapy trials and (b) published findings documenting post-acute dosing impacts of psychedelics on subjective states, meaning, and psychosocial health variables, to produce a set of AE constructs important to evaluate in PAT as well as recommended methods and time frames for their assessment and monitoring. Correspondence between identified potential AEs and current standards for AE assessment was examined, including the extent of coverage of identified AE constructs by 25 existing measures used in relevant research. Results: Fifty-four potential AE terms warranting systematized assessment in PAT were identified, defined, and categorized. Existing measures demonstrated substantial gaps in their coverage of identified AE constructs. Recommendations were developed for how to assess PAT AEs (including patient, clinician, and informant reports), and when to assess over preparation, dosing session, integration, and follow-up. Application of this framework is demonstrated in a preliminary assessment protocol (available in the supplement). Conclusions: This assessment framework addresses the need to capture post-acute dosing AEs in PAT, accounting for its pharmacotherapy and psychotherapy components, as well as documented impacts of psychedelics on worldviews and spirituality.
- Open Access
- 14 May 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e55692
An Immersive Virtual Reality Intervention for Preoperative Anxiety and Distress Among Adults Undergoing Oncological Surgery: Protocol for a 3-Phase Development and Feasibility Trial
Background: Preoperative state anxiety (PSA) is distress and anxiety directly associated with perioperative events. PSA is associated with negative postoperative outcomes such as longer hospital length of stay, increased pain and opioid use, and higher rates of rehospitalization. Psychological prehabilitation, such as education, exposure to hospital environments, and relaxation strategies, has been shown to mitigate PSA; however, there are limited skilled personnel to deliver such interventions in clinical practice. Immersive virtual reality (VR) has the potential for greater accessibility and enhanced integration into an immersive and interactive experience. VR is rarely used in the preoperative setting, but similar forms of stress inoculation training involving exposure to stressful events have improved psychological preparation in contexts such as military deployment. Objective: This study seeks to develop and investigate a targeted PSA intervention in patients undergoing oncological surgery using a single preoperative VR exposure. The primary objectives are to (1) develop a novel VR program for patients undergoing oncological surgery with general anesthesia; (2) assess the feasibility, including acceptability, of a single exposure to this intervention; (3) assess the feasibility, including acceptability, of outcome measures of PSA; and (4) use these results to refine the VR content and outcome measures for a larger trial. A secondary objective is to preliminarily assess the clinical utility of the intervention for PSA. Methods: This study comprises 3 phases. Phase 1 (completed) involved the development of a VR prototype targeting PSA, using multidisciplinary iterative input. Phase 2 (data collection completed) involves examining the feasibility aspects of the VR intervention. This randomized feasibility trial involves assessing the novel VR preoperative intervention compared to a VR control (ie, nature trek) condition and a treatment-as-usual group among patients undergoing breast cancer surgery. Phase 3 will involve refining the prototype based on feasibility findings and input from people with lived experience for a future clinical trial, using focus groups with participants from phase 2. Results: This study was funded in March 2019. Phase 1 was completed in April 2020. Phase 2 data collection was completed in January 2024 and data analysis is ongoing. Focus groups were completed in February 2024. Both the feasibility study and focus groups will contribute to further refinement of the initial VR prototype (phase 3), with the final simulation to be completed by mid-2024. Conclusions: The findings from this work will contribute to the limited body of research examining feasible and broadly accessible interventions for PSA. Knowledge gained from this research will contribute to the final development of a novel VR intervention to be tested in a large population of patients with cancer before surgery in a randomized clinical trial. Trial Registration: ClinicalTrials.gov NCT04544618; https://www.clinicaltrials.gov/study/NCT04544618 International Registered Report Identifier (IRRID): DERR1-10.2196/55692
- 14 May 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e55692
Open AccessAn Immersive Virtual Reality Intervention for Preoperative Anxiety and Distress Among Adults Undergoing Oncological Surgery: Protocol for a 3-Phase Development and Feasibility Trial
Background: Preoperative state anxiety (PSA) is distress and anxiety directly associated with perioperative events. PSA is associated with negative postoperative outcomes such as longer hospital length of stay, increased pain and opioid use, and higher rates of rehospitalization. Psychological prehabilitation, such as education, exposure to hospital environments, and relaxation strategies, has been shown to mitigate PSA; however, there are limited skilled personnel to deliver such interventions in clinical practice. Immersive virtual reality (VR) has the potential for greater accessibility and enhanced integration into an immersive and interactive experience. VR is rarely used in the preoperative setting, but similar forms of stress inoculation training involving exposure to stressful events have improved psychological preparation in contexts such as military deployment. Objective: This study seeks to develop and investigate a targeted PSA intervention in patients undergoing oncological surgery using a single preoperative VR exposure. The primary objectives are to (1) develop a novel VR program for patients undergoing oncological surgery with general anesthesia; (2) assess the feasibility, including acceptability, of a single exposure to this intervention; (3) assess the feasibility, including acceptability, of outcome measures of PSA; and (4) use these results to refine the VR content and outcome measures for a larger trial. A secondary objective is to preliminarily assess the clinical utility of the intervention for PSA. Methods: This study comprises 3 phases. Phase 1 (completed) involved the development of a VR prototype targeting PSA, using multidisciplinary iterative input. Phase 2 (data collection completed) involves examining the feasibility aspects of the VR intervention. This randomized feasibility trial involves assessing the novel VR preoperative intervention compared to a VR control (ie, nature trek) condition and a treatment-as-usual group among patients undergoing breast cancer surgery. Phase 3 will involve refining the prototype based on feasibility findings and input from people with lived experience for a future clinical trial, using focus groups with participants from phase 2. Results: This study was funded in March 2019. Phase 1 was completed in April 2020. Phase 2 data collection was completed in January 2024 and data analysis is ongoing. Focus groups were completed in February 2024. Both the feasibility study and focus groups will contribute to further refinement of the initial VR prototype (phase 3), with the final simulation to be completed by mid-2024. Conclusions: The findings from this work will contribute to the limited body of research examining feasible and broadly accessible interventions for PSA. Knowledge gained from this research will contribute to the final development of a novel VR intervention to be tested in a large population of patients with cancer before surgery in a randomized clinical trial. Trial Registration: ClinicalTrials.gov NCT04544618; https://www.clinicaltrials.gov/study/NCT04544618 International Registered Report Identifier (IRRID): DERR1-10.2196/55692
- Top Cited Papers
- 18 April 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (5) , 792-808
Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder
Post-traumatic stress disorder (PTSD) genetics are characterized by lower discoverability than most other psychiatric disorders. The contribution to biological understanding from previous genetic studies has thus been limited. We performed a multi-ancestry meta-analysis of genome-wide association studies across 1,222,882 individuals of European ancestry (137,136 cases) and 58,051 admixed individuals with African and Native American ancestry (13,624 cases). We identified 95 genome-wide significant loci (80 new). Convergent multi-omic approaches identified 43 potential causal genes, broadly classified as neurotransmitter and ion channel synaptic modulators (for example, GRIA1, GRM8 and CACNA1E), developmental, axon guidance and transcription factors (for example, FOXP2, EFNA5 and DCC), synaptic structure and function genes (for example, PCLO, NCAM1 and PDE4B) and endocrine or immune regulators (for example, ESR1, TRAF3 and TANK). Additional top genes influence stress, immune, fear and threat-related processes, previously hypothesized to underlie PTSD neurobiology. These findings strengthen our understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation.
- 18 April 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (5) , 792-808
Top Cited PapersGenome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder
Post-traumatic stress disorder (PTSD) genetics are characterized by lower discoverability than most other psychiatric disorders. The contribution to biological understanding from previous genetic studies has thus been limited. We performed a multi-ancestry meta-analysis of genome-wide association studies across 1,222,882 individuals of European ancestry (137,136 cases) and 58,051 admixed individuals with African and Native American ancestry (13,624 cases). We identified 95 genome-wide significant loci (80 new). Convergent multi-omic approaches identified 43 potential causal genes, broadly classified as neurotransmitter and ion channel synaptic modulators (for example, GRIA1, GRM8 and CACNA1E), developmental, axon guidance and transcription factors (for example, FOXP2, EFNA5 and DCC), synaptic structure and function genes (for example, PCLO, NCAM1 and PDE4B) and endocrine or immune regulators (for example, ESR1, TRAF3 and TANK). Additional top genes influence stress, immune, fear and threat-related processes, previously hypothesized to underlie PTSD neurobiology. These findings strengthen our understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation.
- Open Access
- 17 January 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e46367
Preoperative Virtual Reality to Expose Patients With Breast Cancer to the Operating Room Environment: Feasibility and Pilot Case Series Study
Background: Clinically elevated preoperative distress and anxiety are common among patients undergoing cancer surgery. Preoperative interventions have been developed to mitigate this distress and anxiety but are inconsistent in efficacy and feasibility for broad implementation. Objective: This preliminary pilot study aims to assess the feasibility and utility of a newly developed virtual reality (VR) intervention to expose patients awaiting breast cancer surgery to the operating room environment and a simulation of anesthetic induction. Methods: Patients undergoing breast cancer surgery (N=7) were assigned to the VR intervention or control (treatment as usual) group and completed self-report measures of distress and anxiety before surgery, on the day of surgery, and after surgery (5 and 30 d postoperatively). Those in the intervention group trialed the VR simulation 1 to 2 weeks preoperatively and provided qualitative and quantitative feedback. We assessed the feasibility of recruitment capability and study design and evaluated participants’ impressions of the intervention using self-report rating scales and open-ended questions. We also descriptively examined distress and anxiety levels throughout the duration of the study. Results: Recruitment occurred between December 2021 and December 2022 and progressed slowly (rate: 1 participant/7 wk on average; some hesitancy because of stress and being overwhelmed). All participants who consented to participate completed the entire study. All participants were female and aged 56 (SD 10.56) years on average. In total, 57% (4/7) of the participants were assigned to the intervention group. On average, intervention participants spent 12 minutes engaged in the VR simulation. In general, the intervention was rated favorably (eg, clear information, enjoyable, and attractive presentation; mean% agreement 95.00-96.25, SD 4.79-10.00) and as helpful (mean% agreement 87.50, SD 25.00). Participants described the intervention as realistic (eg, “It was realistic to my past surgical experiences”), impacting their degree of preparedness and expectations for surgery (eg, “The sounds and sights and procedures give you a test run; they prepare you for the actual day”), and having a calming or relaxing effect (eg, “You feel more relaxed for the surgery”). Conclusions: This preoperative VR intervention demonstrated preliminary feasibility among a sample of patients undergoing breast cancer surgery. Results and participant feedback will inform modifications to the VR intervention and the study design of a large-scale randomized controlled trial to examine the efficacy of this intervention. Trial Registration: ClinicalTrials.gov NCT04544618; https://clinicaltrials.gov/study/NCT04544618
- 17 January 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e46367
Open AccessPreoperative Virtual Reality to Expose Patients With Breast Cancer to the Operating Room Environment: Feasibility and Pilot Case Series Study
Background: Clinically elevated preoperative distress and anxiety are common among patients undergoing cancer surgery. Preoperative interventions have been developed to mitigate this distress and anxiety but are inconsistent in efficacy and feasibility for broad implementation. Objective: This preliminary pilot study aims to assess the feasibility and utility of a newly developed virtual reality (VR) intervention to expose patients awaiting breast cancer surgery to the operating room environment and a simulation of anesthetic induction. Methods: Patients undergoing breast cancer surgery (N=7) were assigned to the VR intervention or control (treatment as usual) group and completed self-report measures of distress and anxiety before surgery, on the day of surgery, and after surgery (5 and 30 d postoperatively). Those in the intervention group trialed the VR simulation 1 to 2 weeks preoperatively and provided qualitative and quantitative feedback. We assessed the feasibility of recruitment capability and study design and evaluated participants’ impressions of the intervention using self-report rating scales and open-ended questions. We also descriptively examined distress and anxiety levels throughout the duration of the study. Results: Recruitment occurred between December 2021 and December 2022 and progressed slowly (rate: 1 participant/7 wk on average; some hesitancy because of stress and being overwhelmed). All participants who consented to participate completed the entire study. All participants were female and aged 56 (SD 10.56) years on average. In total, 57% (4/7) of the participants were assigned to the intervention group. On average, intervention participants spent 12 minutes engaged in the VR simulation. In general, the intervention was rated favorably (eg, clear information, enjoyable, and attractive presentation; mean% agreement 95.00-96.25, SD 4.79-10.00) and as helpful (mean% agreement 87.50, SD 25.00). Participants described the intervention as realistic (eg, “It was realistic to my past surgical experiences”), impacting their degree of preparedness and expectations for surgery (eg, “The sounds and sights and procedures give you a test run; they prepare you for the actual day”), and having a calming or relaxing effect (eg, “You feel more relaxed for the surgery”). Conclusions: This preoperative VR intervention demonstrated preliminary feasibility among a sample of patients undergoing breast cancer surgery. Results and participant feedback will inform modifications to the VR intervention and the study design of a large-scale randomized controlled trial to examine the efficacy of this intervention. Trial Registration: ClinicalTrials.gov NCT04544618; https://clinicaltrials.gov/study/NCT04544618
- Open Access
- 21 December 2023
- Published by JMIR Publications Inc. in JMIR Preprints
An Immersive Virtual Reality Intervention for Preoperative Anxiety and Distress Among Adults Undergoing Oncological Surgery: Protocol for a 3-Phase Development and Feasibility Trial (Preprint)
BACKGROUND Preoperative state anxiety (PSA) is distress and anxiety directly associated with perioperative events. PSA is associated with negative postoperative outcomes such as longer hospital length of stay, increased pain and opioid use, and higher rates of rehospitalization. Psychological prehabilitation, such as education, exposure to hospital environments, and relaxation strategies, has been shown to mitigate PSA; however, there are limited skilled personnel to deliver such interventions in clinical practice. Immersive virtual reality (VR) has the potential for greater accessibility and enhanced integration into an immersive and interactive experience. VR is rarely used in the preoperative setting, but similar forms of stress inoculation training involving exposure to stressful events have improved psychological preparation in contexts such as military deployment. OBJECTIVE This study seeks to develop and investigate a targeted PSA intervention in patients undergoing oncological surgery using a single preoperative VR exposure. The primary objectives are to (1) develop a novel VR program for patients undergoing oncological surgery with general anesthesia; (2) assess the feasibility, including acceptability, of a single exposure to this intervention; (3) assess the feasibility, including acceptability, of outcome measures of PSA; and (4) use these results to refine the VR content and outcome measures for a larger trial. A secondary objective is to preliminarily assess the clinical utility of the intervention for PSA. METHODS This study comprises 3 phases. Phase 1 (completed) involved the development of a VR prototype targeting PSA, using multidisciplinary iterative input. Phase 2 (data collection completed) involves examining the feasibility aspects of the VR intervention. This randomized feasibility trial involves assessing the novel VR preoperative intervention compared to a VR control (ie, nature trek) condition and a treatment-as-usual group among patients undergoing breast cancer surgery. Phase 3 will involve refining the prototype based on feasibility findings and input from people with lived experience for a future clinical trial, using focus groups with participants from phase 2. RESULTS This study was funded in March 2019. Phase 1 was completed in April 2020. Phase 2 data collection was completed in January 2024 and data analysis is ongoing. Focus groups were completed in February 2024. Both the feasibility study and focus groups will contribute to further refinement of the initial VR prototype (phase 3), with the final simulation to be completed by mid-2024. CONCLUSIONS The findings from this work will contribute to the limited body of research examining feasible and broadly accessible interventions for PSA. Knowledge gained from this research will contribute to the final development of a novel VR intervention to be tested in a large population of patients with cancer before surgery in a randomized clinical trial. CLINICALTRIAL ClinicalTrials.gov NCT04544618; https://www.clinicaltrials.gov/study/NCT04544618 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/55692
- 21 December 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAn Immersive Virtual Reality Intervention for Preoperative Anxiety and Distress Among Adults Undergoing Oncological Surgery: Protocol for a 3-Phase Development and Feasibility Trial (Preprint)
BACKGROUND Preoperative state anxiety (PSA) is distress and anxiety directly associated with perioperative events. PSA is associated with negative postoperative outcomes such as longer hospital length of stay, increased pain and opioid use, and higher rates of rehospitalization. Psychological prehabilitation, such as education, exposure to hospital environments, and relaxation strategies, has been shown to mitigate PSA; however, there are limited skilled personnel to deliver such interventions in clinical practice. Immersive virtual reality (VR) has the potential for greater accessibility and enhanced integration into an immersive and interactive experience. VR is rarely used in the preoperative setting, but similar forms of stress inoculation training involving exposure to stressful events have improved psychological preparation in contexts such as military deployment. OBJECTIVE This study seeks to develop and investigate a targeted PSA intervention in patients undergoing oncological surgery using a single preoperative VR exposure. The primary objectives are to (1) develop a novel VR program for patients undergoing oncological surgery with general anesthesia; (2) assess the feasibility, including acceptability, of a single exposure to this intervention; (3) assess the feasibility, including acceptability, of outcome measures of PSA; and (4) use these results to refine the VR content and outcome measures for a larger trial. A secondary objective is to preliminarily assess the clinical utility of the intervention for PSA. METHODS This study comprises 3 phases. Phase 1 (completed) involved the development of a VR prototype targeting PSA, using multidisciplinary iterative input. Phase 2 (data collection completed) involves examining the feasibility aspects of the VR intervention. This randomized feasibility trial involves assessing the novel VR preoperative intervention compared to a VR control (ie, nature trek) condition and a treatment-as-usual group among patients undergoing breast cancer surgery. Phase 3 will involve refining the prototype based on feasibility findings and input from people with lived experience for a future clinical trial, using focus groups with participants from phase 2. RESULTS This study was funded in March 2019. Phase 1 was completed in April 2020. Phase 2 data collection was completed in January 2024 and data analysis is ongoing. Focus groups were completed in February 2024. Both the feasibility study and focus groups will contribute to further refinement of the initial VR prototype (phase 3), with the final simulation to be completed by mid-2024. CONCLUSIONS The findings from this work will contribute to the limited body of research examining feasible and broadly accessible interventions for PSA. Knowledge gained from this research will contribute to the final development of a novel VR intervention to be tested in a large population of patients with cancer before surgery in a randomized clinical trial. CLINICALTRIAL ClinicalTrials.gov NCT04544618; https://www.clinicaltrials.gov/study/NCT04544618 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/55692